{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T18:19:40Z","timestamp":1764181180079,"version":"3.46.0"},"reference-count":188,"publisher":"Springer Science and Business Media LLC","issue":"5-6","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Glycoconj J"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10719-025-10197-8","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T07:44:47Z","timestamp":1760427887000},"page":"225-238","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The effects of DPP4 inhibitors, SGLT2 inhibitors and GLP1-RA on the AGE\/RAGE pathway: implications for diabetes and its complications"],"prefix":"10.1007","volume":"42","author":[{"given":"Sajad","family":"Abolfazli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen L.","family":"Atkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tannaz","family":"Jamialahmadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"issue":"7","key":"10197_CR1","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/ejcn.2017.19","volume":"71","author":"M Deepa","year":"2017","unstructured":"Deepa, M., Anjana, R., Mohan, V.: Role of lifestyle factors in the epidemic of diabetes: Lessons learnt from India. Eur. J. Clin. Nutr. 71(7), 825\u2013831 (2017)","journal-title":"Eur. J. Clin. Nutr."},{"issue":"Supplement1","key":"10197_CR2","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.2337\/dc14-S081","volume":"37","author":"AD Association","year":"2014","unstructured":"Association, A.D.: Diagnosis and classification of diabetes mellitus. Diabetes Care. 37(Supplement1), S81\u2013S90 (2014)","journal-title":"Diabetes Care"},{"key":"10197_CR3","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.2337\/dc18-Sint01","volume":"41","author":"A American Diabetes","year":"2018","unstructured":"American Diabetes, A., Introduction: Standards of medical care in diabetes\u20142018. Diabetes Care. 41, S1\u20132 (2018)","journal-title":"Diabetes Care"},{"issue":"3","key":"10197_CR4","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41440-017-0008-y","volume":"41","author":"D Yamazaki","year":"2018","unstructured":"Yamazaki, D., Hitomi, H., Nishiyama, A.: Hypertension with diabetes mellitus complications. Hypertens. Res. 41(3), 147\u2013156 (2018)","journal-title":"Hypertens. Res."},{"issue":"04","key":"10197_CR5","doi-asserted-by":"publisher","first-page":"174","DOI":"10.4103\/ajm.ajm_53_20","volume":"10","author":"MZ Banday","year":"2020","unstructured":"Banday, M.Z., Sameer, A.S., Nissar, S.: Pathophysiology of diabetes: An overview. Avicenna J. Med. 10(04), 174\u2013188 (2020)","journal-title":"Avicenna J. Med."},{"key":"10197_CR6","unstructured":"Wei, Y., Xu, S.A.O., Wu, Z., Zhang, M., Bao, M., He, B.: Exploring the causal relationships between type 2 diabetes and neurological disorders using a Mendelian randomization strategy. (1536\u20135964 (Electronic))."},{"issue":"9","key":"10197_CR7","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41574-022-00690-7","volume":"18","author":"D Tomic","year":"2022","unstructured":"Tomic, D., Shaw, J.E., Magliano, D.J.: The burden and risks of emerging complications of diabetes mellitus. Nature Reviews Endocrinology 18(9), 525\u2013539 (2022)","journal-title":"Nature Reviews Endocrinology"},{"issue":"4","key":"10197_CR8","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s12265-012-9388-1","volume":"5","author":"HD Nickerson","year":"2012","unstructured":"Nickerson, H.D., Dutta, S.: Diabetic complications: Current challenges and opportunities. J. Cardiovasc. Transl. Res. 5(4), 375\u2013379 (2012)","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"10197_CR9","doi-asserted-by":"publisher","first-page":"S133","DOI":"10.1016\/j.dsx.2016.12.022","volume":"11","author":"H Khalil","year":"2017","unstructured":"Khalil, H.: Diabetes microvascular complications\u2014A clinical update. Diabetes Metabolic Syndrome: Clin. Res. Reviews. 11, S133\u2013S9 (2017)","journal-title":"Diabetes Metabolic Syndrome: Clin. Res. Reviews"},{"issue":"1","key":"10197_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/biology10010018","volume":"10","author":"A Charlton","year":"2021","unstructured":"Charlton, A., Garzarella, J., Jandeleit-Dahm, K.A.M., Jha, J.C.: Oxidative stress and inflammation in renal and cardiovascular complications of diabetes. Biology 10(1), 18 (2021)","journal-title":"Biology"},{"issue":"2","key":"10197_CR11","first-page":"153","volume":"14","author":"J Quiroz-Aldave","year":"2023","unstructured":"Quiroz-Aldave, J., Durand-V\u00e1squez, M., Gamarra-Osorio, E., Su\u00e1rez-Rojas, J., Roseboom, P.J., Alcal\u00e1-Mendoza, R., et al.: Diabetic neuropathy: Past, present, and future. Caspian J. Intern. Med. 14(2), 153 (2023)","journal-title":"Caspian J. Intern. Med."},{"issue":"1","key":"10197_CR12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3390\/diabetology3010011","volume":"3","author":"P Ansari","year":"2022","unstructured":"Ansari, P., Tabasumma, N., Snigdha, N.N., Siam, N.H., Panduru, R.V.N.R.S., Azam, S., et al.: Diabetic retinopathy: An overview on mechanisms, pathophysiology and pharmacotherapy. Diabetology. 3(1), 159\u2013175 (2022)","journal-title":"Diabetology"},{"issue":"4","key":"10197_CR13","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.tem.2020.01.007","volume":"31","author":"D Mauricio","year":"2020","unstructured":"Mauricio, D., Alonso, N., Gratac\u00f2s, M.: Chronic diabetes complications: The need to move beyond classical concepts. Trends in Endocrinology & Metabolism 31(4), 287\u2013295 (2020)","journal-title":"Trends in Endocrinology & Metabolism"},{"issue":"1","key":"10197_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00125-018-4711-2","volume":"62","author":"JL Harding","year":"2019","unstructured":"Harding, J.L., Pavkov, M.E., Magliano, D.J., Shaw, J.E., Gregg, E.W.: Global trends in diabetes complications: A review of current evidence. Diabetologia 62(1), 3\u201316 (2019)","journal-title":"Diabetologia"},{"key":"10197_CR15","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","volume":"376","author":"A Rawshani","year":"2017","unstructured":"Rawshani, A., Rawshani, A., Franz\u00e9n, S., Eliasson, B., Svensson, A.M., Miftaraj, M.: Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl. J. Med. 376, 1407\u20131418 (2017)","journal-title":"N Engl. J. Med."},{"key":"10197_CR16","doi-asserted-by":"publisher","unstructured":"Sadeghi, M., Miroliaei, M., Kamyabiamineh, A., Taslimi, P., Ghanadian, M.: The impact of ages on human health and the development of their inhibitors based on natural compounds. Arabian Journal of Chemistry (2023). https:\/\/doi.org\/10.1016\/j.arabjc.2023.105143","DOI":"10.1016\/j.arabjc.2023.105143"},{"key":"10197_CR17","first-page":"48186","volume":"10","author":"M Odjakova","year":"2012","unstructured":"Odjakova, M., Popova, E., Al Sharif, M., Mironova, R.: Plant-derived agents with anti-glycation activity. Glycosylation. 10, 48186 (2012)","journal-title":"Glycosylation"},{"issue":"13","key":"10197_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24132461","volume":"24","author":"C-Y Shen","year":"2019","unstructured":"Shen, C.-Y., Wu, C.-H., Lu, C.-H., Kuo, Y.-M., Li, K.-J., Hsieh, S.-C., et al.: Advanced glycation end products of bovine serum albumin suppressed Th1\/Th2 cytokine but enhanced monocyte IL-6 gene expression via MAPK-ERK and MyD88 transduced NF-\u03baB p50 signaling pathways. Molecules 24(13), 2461 (2019)","journal-title":"Molecules"},{"issue":"4","key":"10197_CR19","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/gerona\/62.4.427","volume":"62","author":"J Uribarri","year":"2007","unstructured":"Uribarri, J., Cai, W., Peppa, M., Goodman, S., Ferrucci, L., Striker, G., et al.: Circulating Glycotoxins and dietary advanced glycation endproducts: Two links to inflammatory response, oxidative stress, and aging. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 62(4), 427\u2013433 (2007)","journal-title":"The Journals of Gerontology Series A: Biological Sciences and Medical Sciences"},{"issue":"7","key":"10197_CR20","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.lfs.2004.09.011","volume":"76","author":"A Rojas","year":"2004","unstructured":"Rojas, A., Morales, M.A.: Advanced glycation and endothelial functions: A link towards vascular complications in diabetes. Life Sci 76(7), 715\u2013730 (2004)","journal-title":"Life Sci"},{"issue":"1","key":"10197_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3164\/jcbn.15-3","volume":"57","author":"MS Ottum","year":"2015","unstructured":"Ottum, M.S., Mistry, A.M.: Advanced glycation end-products: Modifiable environmental factors profoundly mediate insulin resistance. J. Clin. Biochem. Nutr. 57(1), 1\u201312 (2015)","journal-title":"J. Clin. Biochem. Nutr."},{"key":"10197_CR22","doi-asserted-by":"crossref","unstructured":"Boyer, F., Vidot, J.B., Dubourg, A.G., Rondeau, P., Essop, M.F., Bourdon, E.: Oxidative stress and adipocyte biology: focus on the role of AGEs. Oxidative Medicine and Cellular Longevity. ;2015. (2015)","DOI":"10.1155\/2015\/534873"},{"key":"10197_CR23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.mce.2017.06.012","volume":"454","author":"J Zhang","year":"2017","unstructured":"Zhang, J., Zhang, L., Zhang, S., Yu, Q., Xiong, F., Huang, K., et al.: HMGB1, an innate alarmin, plays a critical role in chronic inflammation of adipose tissue in obesity. Mol. Cell. Endocrinol. 454, 103\u2013111 (2017)","journal-title":"Mol. Cell. Endocrinol."},{"key":"10197_CR24","doi-asserted-by":"crossref","unstructured":"Gugliucci, A., Menini, T.: The axis AGE-RAGE-soluble RAGE and oxidative stress in chronic kidney disease. Oxidative Stress and Inflammation in Non-communicable Diseases-Molecular Mechanisms and Perspectives in Therapeutics. :191\u2013208. (2014)","DOI":"10.1007\/978-3-319-07320-0_14"},{"issue":"16","key":"10197_CR25","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1016\/j.jacc.2020.02.056","volume":"75","author":"T Wilcox","year":"2020","unstructured":"Wilcox, T., De Block, C., Schwartzbard, A.Z., Newman, J.D.: Diabetic agents, from Metformin to SGLT2 inhibitors and GLP1 receptor agonists: JACC focus seminar. J. Am. Coll. Cardiol. 75(16), 1956\u20131974 (2020)","journal-title":"J. Am. Coll. Cardiol."},{"key":"10197_CR26","unstructured":"Br\u00f8nden, A., Christensen, M.B., Glintborg, D., Snorgaard, O., Kofoed-Enevoldsen, A., Madsen, G.K., et al.: Effects of DPP-4 inhibitors, GLP-1 receptor agonists, SGLT-2 inhibitors and sulphonylureas on mortality, cardiovascular and renal outcomes in type 2 diabetes: A network meta-analyses-driven approach. (1464\u20135491 (Electronic))."},{"key":"10197_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.116776","author":"H Yaribeygi","year":"2019","unstructured":"Yaribeygi, H., Sathyapalan, T., Sahebkar, A.: Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity. Life Sci (2019). https:\/\/doi.org\/10.1016\/j.lfs.2019.116776","journal-title":"Life Sci"},{"issue":"4","key":"10197_CR28","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3923\/ijp.2024.672.681","volume":"20","author":"Y Wei","year":"2024","unstructured":"Wei, Y., Ma, H., Wei, T.: Comparing efficacy and safety of Glucagon-Like peptide 1 (GLP-1) agonist versus Sodium-Glucose cotransporter 2 (SGLT-2) inhibitors in Chinese patients with type 2 diabetes mellitus: A preliminary study. International Journal of Pharmacology 20(4), 672\u2013681 (2024)","journal-title":"International Journal of Pharmacology"},{"key":"10197_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/dom.13650","volume":"21","author":"E Brown","year":"2019","unstructured":"Brown, E., Rajeev, S.P., Cuthbertson, D.J., Wilding, J.P.: A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co\u2010transporter\u20102 inhibitors. Diabetes Obes. Metabolism. 21, 9\u201318 (2019)","journal-title":"Diabetes Obes. Metabolism"},{"issue":"10","key":"10197_CR30","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.metabol.2014.06.018","volume":"63","author":"JP Wilding","year":"2014","unstructured":"Wilding, J.P.: The role of the kidneys in glucose homeostasis in type 2 diabetes: Clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. Metabolism 63(10), 1228\u20131237 (2014)","journal-title":"Metabolism"},{"key":"10197_CR31","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212264","author":"EM Vivian","year":"2014","unstructured":"Vivian, E.M.: Sodium-glucose co-transporter 2 (SGLT2) inhibitors: A growing class of antidiabetic agents. Drugs in Context (2014). https:\/\/doi.org\/10.7573\/dic.212264","journal-title":"Drugs in Context"},{"issue":"1","key":"10197_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-019-0828-y","volume":"18","author":"CMA Cefalo","year":"2019","unstructured":"Cefalo, C.M.A., Cinti, F., Moffa, S., Impronta, F., Sorice, G.P., Mezza, T., et al.: Sotagliflozin, the first dual SGLT inhibitor: Current outlook and perspectives. Cardiovasc. Diabetol. 18(1), 1\u201314 (2019)","journal-title":"Cardiovasc. Diabetol."},{"issue":"7","key":"10197_CR33","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/j.1463-1326.2011.01406.x","volume":"13","author":"S Sha","year":"2011","unstructured":"Sha, S., Devineni, D., Ghosh, A., Polidori, D., Chien, S., Wexler, D., et al.: Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes. Metabolism. 13(7), 669\u2013672 (2011)","journal-title":"Diabetes Obes. Metabolism"},{"issue":"2","key":"10197_CR34","doi-asserted-by":"publisher","first-page":"e30555","DOI":"10.1371\/journal.pone.0030555","volume":"7","author":"Y Liang","year":"2012","unstructured":"Liang, Y., Arakawa, K., Ueta, K., Matsushita, Y., Kuriyama, C., Martin, T., et al.: Effect of Canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PloS One. 7(2), e30555 (2012)","journal-title":"PloS One"},{"issue":"10296","key":"10197_CR35","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","volume":"398","author":"E Brown","year":"2021","unstructured":"Brown, E., Heerspink, H.J., Cuthbertson, D.J., Wilding, J.P.: SGLT2 inhibitors and GLP-1 receptor agonists: Established and emerging indications. Lancet 398(10296), 262\u2013276 (2021)","journal-title":"Lancet"},{"issue":"Supplement2","key":"10197_CR36","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.2337\/db06-S020","volume":"55","author":"GE Lim","year":"2006","unstructured":"Lim, G.E., Brubaker, P.L.: Glucagon-like peptide 1 secretion by The L-cell: The view from within. Diabetes 55(Supplement2), S70\u2013S7 (2006)","journal-title":"Diabetes"},{"issue":"11","key":"10197_CR37","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.3390\/nu12113304","volume":"12","author":"Y Diz-Chaves","year":"2020","unstructured":"Diz-Chaves, Y., Herrera-P\u00e9rez, S., Gonz\u00e1lez-Mat\u00edas, L.C., Lamas, J.A., Mallo, F.: Glucagon-Like Peptide-1 (GLP-1) in the integration of neural and endocrine responses to stress. Nutrients. 12(11), 3304 (2020)","journal-title":"Nutrients"},{"issue":"11","key":"10197_CR38","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/s41574-020-0399-8","volume":"16","author":"CF Deacon","year":"2020","unstructured":"Deacon, C.F.: Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nature Reviews Endocrinology 16(11), 642\u2013653 (2020)","journal-title":"Nature Reviews Endocrinology"},{"key":"10197_CR39","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1007\/s12020-015-0841-1","volume":"52","author":"E Bekiari","year":"2016","unstructured":"Bekiari, E., Rizava, C., Athanasiadou, E., Papatheodorou, K., Liakos, A., Karagiannis, T., et al.: Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes. Endocrine. 52, 458\u2013480 (2016)","journal-title":"Endocrine"},{"key":"10197_CR40","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40265-016-0686-9","volume":"77","author":"LJ Scott","year":"2017","unstructured":"Scott, L.J.: Sitagliptin: A review in type 2 diabetes. Drugs 77, 209\u2013224 (2017)","journal-title":"Drugs"},{"key":"10197_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s40200-016-0256-4","author":"A Sharma","year":"2016","unstructured":"Sharma, A., Paliwal, G., Upadhyay, N., Tiwari, A.: Retraction Note: Therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment. J. Diabetes Metab. Disord (2016). https:\/\/doi.org\/10.1186\/s40200-016-0256-4","journal-title":"J. Diabetes Metab. Disord"},{"key":"10197_CR42","doi-asserted-by":"crossref","unstructured":"Sharma, A., Paliwal, G., Upadhyay, N., Tiwari, A.: Therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment. J. Diabetes Metab. Disord. ;14. (2015)","DOI":"10.1186\/s40200-015-0143-4"},{"key":"10197_CR43","doi-asserted-by":"crossref","unstructured":"Krarup, T., Madsbad, S., Holst, J. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients T., Vilsb\u00f8ll, et al.: Defective insulin response to GIP in Type II diabetes. Diabetologia. ;45(8). (2002)","DOI":"10.1007\/s00125-002-0878-6"},{"issue":"4","key":"10197_CR44","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.2337\/db10-1332","volume":"60","author":"N Mentis","year":"2011","unstructured":"Mentis, N., Vardarli, I., K\u00f6the, L.D., Holst, J.J., Deacon, C.F., Theodorakis, M., et al.: GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes. Diabetes. 60(4), 1270\u20131276 (2011)","journal-title":"Diabetes"},{"key":"10197_CR45","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s12020-015-0733-4","volume":"51","author":"A Morita","year":"2016","unstructured":"Morita, A., Mukai, E., Hiratsuka, A., Takatani, T., Iwanaga, T., Lee, E.Y., et al.: Distinct effects of dipeptidyl peptidase-4 inhibitor and glucagon-like peptide-1 receptor agonist on islet morphology and function. Endocrine 51, 429\u2013439 (2016)","journal-title":"Endocrine"},{"issue":"10","key":"10197_CR46","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nrneph.2017.123","volume":"13","author":"MH Muskiet","year":"2017","unstructured":"Muskiet, M.H., Tonneijck, L., Smits, M.M., Van Baar, M.J., Kramer, M.H., Hoorn, E.J., et al.: GLP-1 and the kidney: From physiology to Pharmacology and outcomes in diabetes. Nat. Rev. Nephrol 13(10), 605\u2013628 (2017)","journal-title":"Nat. Rev. Nephrol"},{"issue":"4","key":"10197_CR47","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41581-020-00367-2","volume":"17","author":"RZ Alicic","year":"2021","unstructured":"Alicic, R.Z., Cox, E.J., Neumiller, J.J., Tuttle, K.R.: Incretin drugs in diabetic kidney disease: Biological mechanisms and clinical evidence. Nat. Rev. Nephrol. 17(4), 227\u2013244 (2021)","journal-title":"Nat. Rev. Nephrol."},{"issue":"2","key":"10197_CR48","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3390\/antiox10020246","volume":"10","author":"D Kawanami","year":"2021","unstructured":"Kawanami, D., Takashi, Y., Takahashi, H., Motonaga, R., Tanabe, M.: Renoprotective effects of DPP-4 inhibitors. Antioxidants. 10(2), 246 (2021)","journal-title":"Antioxidants"},{"issue":"1","key":"10197_CR49","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1124\/jpet.111.181529","volume":"340","author":"R Bianchi","year":"2012","unstructured":"Bianchi, R., Cervellini, I., Porretta-Serapiglia, C., Oggioni, N., Burkey, B., Ghezzi, P., et al.: Beneficial effects of PKF275-055, a novel, selective, orally bioavailable, long-acting dipeptidyl peptidase IV inhibitor in streptozotocin-induced diabetic peripheral neuropathy. J. Pharmacol. Exp. Ther. 340(1), 64\u201372 (2012)","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"8","key":"10197_CR50","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3390\/ijms17081223","volume":"17","author":"D Kawanami","year":"2016","unstructured":"Kawanami, D., Matoba, K., Sango, K., Utsunomiya, K.: Incretin-based therapies for diabetic complications: Basic mechanisms and clinical evidence. Int. J. Mol. Sci. 17(8), 1223 (2016)","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10197_CR51","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/jnc.13439","volume":"136","author":"K Tsuboi","year":"2016","unstructured":"Tsuboi, K., Mizukami, H., Inaba, W., Baba, M., Yagihashi, S.: The dipeptidyl peptidase IV inhibitor vildagliptin suppresses development of neuropathy in diabetic rodents: Effects on peripheral sensory nerve function, structure and molecular changes. J. Neurochem. 136(4), 859\u2013870 (2016)","journal-title":"J. Neurochem."},{"issue":"9","key":"10197_CR52","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/j.bbadis.2014.04.013","volume":"1842","author":"A Gon\u00e7alves","year":"2014","unstructured":"Gon\u00e7alves, A., Marques, C., Leal, E., Ribeiro, C.F., Reis, F., Ambr\u00f3sio, A.F., et al.: Dipeptidyl peptidase-IV Inhibition prevents blood\u2013retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats. Biochimica et Biophysica Acta (BBA) 1842(9), 1454\u20131463 (2014)","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"12","key":"10197_CR53","doi-asserted-by":"publisher","first-page":"e0167853","DOI":"10.1371\/journal.pone.0167853","volume":"11","author":"N Dietrich","year":"2016","unstructured":"Dietrich, N., Kolibabka, M., Busch, S., Bugert, P., Kaiser, U., Lin, J., et al.: The DPP4 inhibitor linagliptin protects from experimental diabetic retinopathy. PloS One. 11(12), e0167853 (2016)","journal-title":"PloS One"},{"issue":"4","key":"10197_CR54","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000354116","volume":"50","author":"S Maeda","year":"2013","unstructured":"Maeda, S., Yamagishi, S., Matsui, T., Nakashima, S., Ojima, A., Maeda, S., et al.: Beneficial effects of vildagliptin on retinal injury in obese type 2 diabetic rats. Ophthalmic Res 50(4), 221\u2013226 (2013)","journal-title":"Ophthalmic Res"},{"key":"10197_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2025.1533820","volume":"12","author":"X Liu","year":"2025","unstructured":"Liu, X., Zhao, H., Liu, S., Wen, S., Fan, W., Xie, Q., et al.: Comparison of the effects of Metformin and empagliflozin on cardiac function in heart failure with preserved ejection fraction mice. Front. Cardiovasc. Med. 12, 1533820 (2025)","journal-title":"Front. Cardiovasc. Med."},{"issue":"4","key":"10197_CR56","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1002\/jcp.26760","volume":"234","author":"H Yaribeygi","year":"2019","unstructured":"Yaribeygi, H., Atkin, S.L., Butler, A.E., Sahebkar, A.: Sodium\u2013glucose cotransporter inhibitors and oxidative stress: An update. J. Cell. Physiol. 234(4), 3231\u20133237 (2019)","journal-title":"J. Cell. Physiol."},{"issue":"1","key":"10197_CR57","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/jcp.26851","volume":"234","author":"H Yaribeygi","year":"2018","unstructured":"Yaribeygi, H., Butler, A.E., Atkin, S.L., Katsiki, N., Sahebkar, A.: Sodium\u2013glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways. J. Cell. Physiol. 234(1), 223\u2013230 (2018)","journal-title":"J. Cell. Physiol."},{"issue":"9","key":"10197_CR58","doi-asserted-by":"publisher","first-page":"4502","DOI":"10.7150\/thno.54498","volume":"11","author":"Z Liu","year":"2021","unstructured":"Liu, Z., Ma, X., Ilyas, I., Zheng, X., Luo, S., Little, P.J., et al.: Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: From Pharmacology to pre-clinical and clinical therapeutics. Theranostics 11(9), 4502\u20134515 (2021)","journal-title":"Theranostics"},{"key":"10197_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcte.2024.100335","volume":"35","author":"I Hasan","year":"2024","unstructured":"Hasan, I., Rashid, T., Jaikaransingh, V., Heilig, C., Abdel-Rahman, E.M., Awad, A.S.: SGLT2 inhibitors: Beyond glycemic control. Journal of Clinical & Translational Endocrinology 35, 100335 (2024)","journal-title":"Journal of Clinical & Translational Endocrinology"},{"issue":"4","key":"10197_CR60","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.hfc.2022.03.005","volume":"18","author":"V Vallon","year":"2022","unstructured":"Vallon, V.: Renoprotective effects of SGLT2 inhibitors. Heart Fail. Clin. 18(4), 539\u2013549 (2022)","journal-title":"Heart Fail. Clin."},{"issue":"4","key":"10197_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24044144","volume":"24","author":"AP Vargas-Delgado","year":"2023","unstructured":"Vargas-Delgado, A.P., Arteaga Herrera, E., Tumbaco Mite, C., Delgado Cedeno, P., Van Loon, M.C., Badimon, J.J.: Renal and cardiovascular metabolic impact caused by ketogenesis of the SGLT2 inhibitors. Int. J. Mol. Sci. 24(4), 4144 (2023)","journal-title":"Int. J. Mol. Sci."},{"key":"10197_CR62","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","volume":"62","author":"HJ Heerspink","year":"2019","unstructured":"Heerspink, H.J., Perco, P., Mulder, S., Leierer, J., Hansen, M.K., Heinzel, A., et al.: Canagliflozin reduces inflammation and fibrosis biomarkers: A potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia 62, 1154\u20131166 (2019)","journal-title":"Diabetologia"},{"issue":"1","key":"10197_CR63","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1177\/1479164117733626","volume":"15","author":"T Gaspari","year":"2018","unstructured":"Gaspari, T., Spizzo, I., Liu, H., Hu, Y., Simpson, R.W., Widdop, R.E., et al.: Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for Inhibition of atherogenesis. Diabetes and Vascular Disease Research 15(1), 64\u201373 (2018)","journal-title":"Diabetes and Vascular Disease Research"},{"issue":"5","key":"10197_CR64","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1681\/ASN.2020010010","volume":"31","author":"M Packer","year":"2020","unstructured":"Packer, M.: Role of impaired nutrient and oxygen deprivation signaling and deficient autophagic flux in diabetic CKD development: Implications for Understanding the effects of sodium-glucose cotransporter 2-inhibitors. Journal of the American Society of Nephrology 31(5), 907 (2020)","journal-title":"Journal of the American Society of Nephrology"},{"issue":"16","key":"10197_CR65","doi-asserted-by":"publisher","first-page":"8786","DOI":"10.3390\/ijms22168786","volume":"22","author":"W Durante","year":"2021","unstructured":"Durante, W., Behnammanesh, G., Peyton, K.J.: Effects of sodium-glucose co-transporter 2 inhibitors on vascular cell function and arterial remodeling. Int. J. Mol. Sci. 22(16), 8786 (2021)","journal-title":"Int. J. Mol. Sci."},{"issue":"23","key":"10197_CR66","doi-asserted-by":"publisher","first-page":"7213","DOI":"10.3390\/molecules26237213","volume":"26","author":"A Pawlos","year":"2021","unstructured":"Pawlos, A., Broncel, M., Wo\u017aniak, E., Gorzelak-Pabi\u015b, P.: Neuroprotective effect of SGLT2 inhibitors. Molecules. 26(23), 7213 (2021)","journal-title":"Molecules"},{"key":"10197_CR67","doi-asserted-by":"publisher","first-page":"8867875","DOI":"10.1155\/2020\/8867875","volume":"2020","author":"W Sha","year":"2020","unstructured":"Sha, W., Wen, S., Chen, L., Xu, B., Lei, T., Zhou, L.: The role of SGLT2 inhibitor on the treatment of diabetic retinopathy. J. Diabetes Res. 2020, 8867875 (2020)","journal-title":"J. Diabetes Res."},{"issue":"Supplement2","key":"10197_CR68","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad655.2825","volume":"44","author":"EM Cordeanu","year":"2023","unstructured":"Cordeanu, E.M., Qureshi, A.W., Mroueh, A., Mazzucotelli, J.P., Stephan, D., Schini-Kerth, V.: GLP1 receptor agonists exhibit antioxidant and anti-inflammatory properties in human heart tissue via the canonical GLP1 receptor expression through a AMPK-mediated pathway. Eur. Heart J. 44(Supplement2), ehad6552825 (2023)","journal-title":"Eur. Heart J."},{"key":"10197_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2019.154001","author":"G Ranjbar","year":"2019","unstructured":"Ranjbar, G., Mikhailidis, D.P., Sahebkar, A.: Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box! Metabolism (2019). https:\/\/doi.org\/10.1016\/j.metabol.2019.154001","journal-title":"Metabolism"},{"key":"10197_CR70","doi-asserted-by":"crossref","unstructured":"Rezaei, S., Tabrizi, R., Nowrouzi-Sohrabi, P., Jalali, M., Atkin, S.L., Al-Rasadi, K., et al.: GLP-1 Receptor Agonist Effects on Lipid and Liver Profiles in Patients with Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis. Canadian Journal of Gastroenterology and Hepatology. ;2021. (2021)","DOI":"10.1155\/2021\/8936865"},{"issue":"1","key":"10197_CR71","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.drudis.2018.08.005","volume":"24","author":"H Yaribeygi","year":"2019","unstructured":"Yaribeygi, H., Katsiki, N., Butler, A.E., Sahebkar, A.: Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys. Drug Discovery Today 24(1), 256\u2013262 (2019)","journal-title":"Drug Discovery Today"},{"issue":"4","key":"10197_CR72","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s13410-020-00879-4","volume":"40","author":"S Chowdhury","year":"2020","unstructured":"Chowdhury, S., Goswami, S.: GLP1 agonists beyond glycemic control\u2014redefining their role. International Journal of Diabetes in Developing Countries 40(4), 461\u2013463 (2020)","journal-title":"International Journal of Diabetes in Developing Countries"},{"key":"10197_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910822","author":"A Winiarska","year":"2021","unstructured":"Winiarska, A., Knysak, M., Nabrdalik, K., Gumprecht, J., Stomp\u00f3r, T.: Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists. International Journal of Molecular Sciences (2021). https:\/\/doi.org\/10.3390\/ijms221910822","journal-title":"International Journal of Molecular Sciences"},{"issue":"3","key":"10197_CR74","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.mvr.2012.06.008","volume":"84","author":"Y Ishibashi","year":"2012","unstructured":"Ishibashi, Y., Matsui, T., Ojima, A., Nishino, Y., Nakashima, S., Maeda, S., et al.: Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A. Microvasc. Res. 84(3), 395\u2013398 (2012)","journal-title":"Microvasc. Res."},{"issue":"5","key":"10197_CR75","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","volume":"129","author":"DZ Cherney","year":"2014","unstructured":"Cherney, D.Z., Perkins, B.A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., et al.: Renal hemodynamic effect of sodium-glucose cotransporter 2 Inhibition in patients with type 1 diabetes mellitus. Circulation 129(5), 587\u2013597 (2014)","journal-title":"Circulation"},{"issue":"2","key":"10197_CR76","doi-asserted-by":"publisher","first-page":"136","DOI":"10.23876\/j.krcp.22.001","volume":"41","author":"JH Yu","year":"2022","unstructured":"Yu, J.H., Park, S.Y., Kim, N.H., Seo, J.A.: GLP-1 receptor agonists in diabetic kidney disease: Current evidence and future directions. Kidney Res. Clin. Pract. 41(2), 136 (2022)","journal-title":"Kidney Res. Clin. Pract."},{"issue":"1","key":"10197_CR77","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/1389203721999201208195901","volume":"22","author":"K Mehta","year":"2021","unstructured":"Mehta, K., Behl, T., Kumar, A., Uddin, M.S., Zengin, G., Arora, S.: Deciphering the neuroprotective role of glucagon-like Peptide-1 agonists in diabetic neuropathy: Current perspective and future directions. Curr. Protein Pept. Sci. 22(1), 4\u201318 (2021)","journal-title":"Curr. Protein Pept. Sci."},{"issue":"3","key":"10197_CR78","first-page":"316","volume":"20","author":"S Zahoor","year":"2017","unstructured":"Zahoor, S., Haji, A., Battoo, A., Qurieshi, M., Mir, W., Shah, M., et al.: Effects of incretin-based therapies on diabetic microvascular complications. Endocrinol. Metabolism. 20(3), 316\u2013325 (2017)","journal-title":"Endocrinol. Metabolism"},{"issue":"12","key":"10197_CR79","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.7150\/ijms.20962","volume":"14","author":"X Cai","year":"2017","unstructured":"Cai, X., Li, J., Wang, M., She, M., Tang, Y., Li, J., et al.: GLP-1 treatment improves diabetic retinopathy by alleviating autophagy through GLP-1R-ERK1\/2-HDAC6 signaling pathway. Int. J. Med. Sci. 14(12), 1203\u20131212 (2017)","journal-title":"Int. J. Med. Sci."},{"issue":"3","key":"10197_CR80","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.26599\/FSHW.2022.9250094","volume":"13","author":"H Peng","year":"2024","unstructured":"Peng, H., Gao, Y., Zeng, C., Hua, R., Guo, Y., Wang, Y., et al.: Effects of Maillard reaction and its product ages on aging and age-related diseases. Food Science and Human Wellness 13(3), 1118\u20131134 (2024)","journal-title":"Food Science and Human Wellness"},{"key":"10197_CR81","first-page":"66","volume":"154","author":"L Maillard","year":"1912","unstructured":"Maillard, L.: Reaction of amino acids on sugars: Formation of melanoidins by a systematic way. Compt Rend. Acad. Sci. 154, 66\u201368 (1912)","journal-title":"Compt Rend. Acad. Sci."},{"issue":"1","key":"10197_CR82","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqz006","volume":"161","author":"HH Ruiz","year":"2020","unstructured":"Ruiz, H.H., Ramasamy, R., Schmidt, A.M.: Advanced glycation end products: Building on the concept of the common soil in metabolic disease. Endocrinology 161(1), bqz006 (2020)","journal-title":"Endocrinology"},{"key":"10197_CR83","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.fct.2013.06.052","volume":"60","author":"MW Poulsen","year":"2013","unstructured":"Poulsen, M.W., Hedegaard, R.V., Andersen, J.M., De Courten, B., B\u00fcgel, S., Nielsen, J., et al.: Advanced glycation endproducts in food and their effects on health. Food Chem. Toxicol. 60, 10\u201337 (2013)","journal-title":"Food Chem. Toxicol."},{"issue":"2","key":"10197_CR84","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1021\/pr800858h","volume":"8","author":"Q Zhang","year":"2009","unstructured":"Zhang, Q., Ames, J.M., Smith, R.D., Baynes, J.W., Metz, T.O.: A perspective on the Maillard reaction and the analysis of protein glycation by mass spectrometry: Probing the pathogenesis of chronic disease. J. Proteome Res. 8(2), 754\u2013769 (2009)","journal-title":"J. Proteome Res."},{"issue":"9","key":"10197_CR85","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.3390\/cells8091101","volume":"8","author":"J Lund","year":"2019","unstructured":"Lund, J., Ouwens, D.M., Wettergreen, M., Bakke, S.S., Thoresen, G.H., Aas, V.: Increased Glycolysis and higher lactate production in hyperglycemic myotubes. Cells. 8(9), 1101 (2019)","journal-title":"Cells"},{"issue":"9","key":"10197_CR86","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1021\/acs.jafc.7b05943","volume":"66","author":"J-A Lin","year":"2018","unstructured":"Lin, J.-A., Wu, C.-H., Yen, G.-C.: Perspective of advanced glycation end products on human health. J. Agric. Food Chem. 66(9), 2065\u20132070 (2018)","journal-title":"J. Agric. Food Chem."},{"issue":"11","key":"10197_CR87","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1016\/j.cellsig.2013.06.013","volume":"25","author":"J Xie","year":"2013","unstructured":"Xie, J., M\u00e9ndez, J.D., M\u00e9ndez-Valenzuela, V., Aguilar-Hern\u00e1ndez, M.M.: Cellular signalling of the receptor for advanced glycation end products (RAGE). Cell. Signal. 25(11), 2185\u20132197 (2013)","journal-title":"Cell. Signal."},{"issue":"2\u20133","key":"10197_CR88","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0167-4889(00)00087-2","volume":"1498","author":"AM Schmidt","year":"2000","unstructured":"Schmidt, A.M., Du Yan, S., Yan, S.F., Stern, D.M.: The biology of the receptor for advanced glycation end products and its ligands. Biochimica et biophysica acta (BBA)-Molecular cell research 1498(2\u20133), 99\u2013111 (2000)","journal-title":"Biochimica et biophysica acta (BBA)-Molecular cell research"},{"issue":"21","key":"10197_CR89","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.2174\/092986710791331086","volume":"17","author":"P Alexiou","year":"2010","unstructured":"Alexiou, P., Chatzopoulou, M., Pegklidou, K., Demopoulos, V.: RAGE: A multi-ligand receptor unveiling novel insights in health and disease. Curr. Med. Chem. 17(21), 2232\u20132252 (2010)","journal-title":"Curr. Med. Chem."},{"issue":"3","key":"10197_CR90","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10522-019-09808-3","volume":"20","author":"T Teissier","year":"2019","unstructured":"Teissier, T., Boulanger, \u00c9.: The receptor for advanced glycation end-products (RAGE) is an important pattern recognition receptor (PRR) for inflammaging. Biogerontology 20(3), 279\u2013301 (2019)","journal-title":"Biogerontology"},{"key":"10197_CR91","doi-asserted-by":"crossref","unstructured":"Chuah, Y.K., Basir, R., Talib, H., Tie, T.H., Nordin, N.: Receptor for advanced glycation end products and its involvement in inflammatory diseases. International journal of inflammation. ;2013. (2013)","DOI":"10.1155\/2013\/403460"},{"issue":"1","key":"10197_CR92","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1262-3636(07)70164-7","volume":"31","author":"G Prevost","year":"2005","unstructured":"Prevost, G., Fajardy, I., Besmond, C., Balkau, B., Tichet, J., Fontaine, P., et al.: Polymorphisms of the receptor of advanced glycation endproducts (RAGE) and the development of nephropathy in type 1 diabetic patients. Diabetes Metab. 31(1), 35\u201339 (2005)","journal-title":"Diabetes Metab."},{"issue":"4","key":"10197_CR93","doi-asserted-by":"publisher","DOI":"10.5808\/GI.2013.11.4.224","volume":"11","author":"EJ Lee","year":"2013","unstructured":"Lee, E.J., Park, J.H.: Receptor for advanced glycation endproducts (RAGE), its ligands, and soluble RAGE: Potential biomarkers for diagnosis and therapeutic targets for human renal diseases. Genomics & Informatics 11(4), 224 (2013)","journal-title":"Genomics & Informatics"},{"key":"10197_CR94","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.neulet.2018.02.049","volume":"672","author":"X Jiang","year":"2018","unstructured":"Jiang, X., Wang, X., Tuo, M., Ma, J., Xie, A.: RAGE and its emerging role in the pathogenesis of parkinson\u2019s disease. Neurosci. Lett. 672, 65\u201369 (2018)","journal-title":"Neurosci. Lett."},{"issue":"5","key":"10197_CR95","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1096\/fj.07-9909com","volume":"22","author":"BI Hudson","year":"2008","unstructured":"Hudson, B.I., Carter, A.M., Harja, E., Kalea, A.Z., Arriero, M., Yang, H., et al.: Identification, classification, and expression of RAGE gene splice variants. FASEB J. 22(5), 1572\u20131580 (2008)","journal-title":"FASEB J."},{"issue":"10","key":"10197_CR96","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.bcp.2010.01.013","volume":"79","author":"SF Yan","year":"2010","unstructured":"Yan, S.F., Ramasamy, R., Schmidt, A.M.: Soluble RAGE: Therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochemical Pharmacology 79(10), 1379\u20131386 (2010)","journal-title":"Biochemical Pharmacology"},{"issue":"4","key":"10197_CR97","doi-asserted-by":"publisher","first-page":"G556","DOI":"10.1152\/ajpgi.00055.2006","volume":"291","author":"KG Raman","year":"2006","unstructured":"Raman, K.G., Sappington, P.L., Yang, R., Levy, R.M., Prince, J.M., Liu, S., et al.: The role of RAGE in the pathogenesis of intestinal barrier dysfunction after hemorrhagic shock. American Journal of Physiology-Gastrointestinal and Liver Physiology 291(4), G556\u2013G65 (2006)","journal-title":"American Journal of Physiology-Gastrointestinal and Liver Physiology"},{"issue":"6","key":"10197_CR98","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.18632\/aging.101860","volume":"11","author":"F Scavello","year":"2019","unstructured":"Scavello, F., Zeni, F., Tedesco, C.C., Mens\u00e0, E., Veglia, F., Procopio, A.D., et al.: Modulation of soluble receptor for advanced glycation end-products (RAGE) isoforms and their ligands in healthy aging. Aging (Albany NY) 11(6), 1648 (2019)","journal-title":"Aging (Albany NY)"},{"issue":"12","key":"10197_CR99","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1161\/01.RES.0000103862.26506.3D","volume":"93","author":"SF Yan","year":"2003","unstructured":"Yan, S.F., Ramasamy, R., Naka, Y., Schmidt, A.M.: Glycation, inflammation, and RAGE: A scaffold for the macrovascular complications of diabetes and beyond. Circul. Res. 93(12), 1159\u20131169 (2003)","journal-title":"Circul. Res."},{"key":"10197_CR100","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s12035-017-0419-4","volume":"55","author":"K G\u0105siorowski","year":"2018","unstructured":"G\u0105siorowski, K., Brokos, B., Echeverria, V., Barreto, G.E., Leszek, J.: RAGE-TLR crosstalk sustains chronic inflammation in neurodegeneration. Mol. Neurobiol. 55, 1463\u20131476 (2018)","journal-title":"Mol. Neurobiol."},{"issue":"1","key":"10197_CR101","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.201900934","volume":"65","author":"D Sergi","year":"2021","unstructured":"Sergi, D., Boulestin, H., Campbell, F.M., Williams, L.M.: The role of dietary advanced glycation end products in metabolic dysfunction. Mol. Nutr. Food Res. 65(1), 1900934 (2021)","journal-title":"Mol. Nutr. Food Res."},{"issue":"2","key":"10197_CR102","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1089\/met.2004.2.82","volume":"2","author":"JP Sutherland","year":"2004","unstructured":"Sutherland, J.P., McKinley, B., Eckel, R.H.: The metabolic syndrome and inflammation. Metab. Syndr. Relat. Disord. 2(2), 82\u2013104 (2004)","journal-title":"Metab. Syndr. Relat. Disord."},{"issue":"1","key":"10197_CR103","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11010-016-2878-8","volume":"426","author":"KC Nandipati","year":"2017","unstructured":"Nandipati, K.C., Subramanian, S., Agrawal, D.K.: Protein kinases: Mechanisms and downstream targets in inflammation-mediated obesity and insulin resistance. Mol. Cell. Biochem. 426(1), 27\u201345 (2017)","journal-title":"Mol. Cell. Biochem."},{"issue":"1","key":"10197_CR104","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00312-6","volume":"5","author":"H Yu","year":"2020","unstructured":"Yu, H., Lin, L., Zhang, Z., Zhang, H., Hu, H.: Targeting NF-\u03baB pathway for the therapy of diseases: Mechanism and clinical study. Signal Transduction and Targeted Therapy 5(1), 209 (2020)","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10197_CR105","doi-asserted-by":"crossref","unstructured":"Cheng, Y., Wang, L., Zhang, S., Jian, W., Zeng, B., Liang, L., et al.: The investigation of Nf\u03bab inhibitors to block cell proliferation in OSCC cells lines. Curr. Med. Chem. (2024)","DOI":"10.2174\/0109298673309489240816063313"},{"issue":"1","key":"10197_CR106","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2016.12.012","volume":"168","author":"Q Zhang","year":"2017","unstructured":"Zhang, Q., Lenardo, M.J., Baltimore, D.: 30 years of NF-\u03baB: A blossoming of relevance to human pathobiology. Cell. 168(1), 37\u201357 (2017)","journal-title":"Cell"},{"issue":"16","key":"10197_CR107","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168590","volume":"22","author":"M Khalid","year":"2021","unstructured":"Khalid, M., Alkaabi, J., Khan, M.A.B., Adem, A.: Insulin signal transduction perturbations in insulin resistance. Int. J. Mol. Sci. 22(16), 8590 (2021)","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10197_CR108","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3390\/cells9030706","volume":"9","author":"JHM Yung","year":"2020","unstructured":"Yung, J.H.M., Giacca, A.: Role of c-Jun N-terminal kinase (JNK) in obesity and type 2 diabetes. Cells. 9(3), 706 (2020)","journal-title":"Cells"},{"issue":"6","key":"10197_CR109","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1007\/s11010-022-04587-x","volume":"478","author":"K Ramasubbu","year":"2023","unstructured":"Ramasubbu, K., Devi Rajeswari, V.: Impairment of insulin signaling pathway PI3K\/Akt\/mTOR and insulin resistance induced ages on diabetes mellitus and neurodegenerative diseases: A perspective review. Mol. Cell. Biochem. 478(6), 1307\u20131324 (2023)","journal-title":"Mol. Cell. Biochem."},{"key":"10197_CR110","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11010-016-2878-8","volume":"426","author":"KC Nandipati","year":"2017","unstructured":"Nandipati, K.C., Subramanian, S., Agrawal, D.K.: Protein kinases: Mechanisms and downstream targets in inflammation-mediated obesity and insulin resistance. Mol. Cell. Biochem. 426, 27\u201345 (2017)","journal-title":"Mol. Cell. Biochem."},{"issue":"2","key":"10197_CR111","doi-asserted-by":"publisher","first-page":"76","DOI":"10.2174\/1872214810666161020154905","volume":"10","author":"V Sidarala","year":"2016","unstructured":"Sidarala, V., Kowluru, A.: The regulatory roles of mitogen-activated protein kinase (MAPK) pathways in health and diabetes: Lessons learned from the pancreatic \u03b2-cell. Recent Pat. Endocr., Metab. Immune Drug Discovery 10(2), 76\u201384 (2016)","journal-title":"Recent Pat. Endocr., Metab. Immune Drug Discovery"},{"key":"10197_CR112","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2019.01038","volume":"10","author":"T Kong","year":"2019","unstructured":"Kong, T., Liu, M., Ji, B., Bai, B., Cheng, B., Wang, C.: Role of the extracellular signal-regulated kinase 1\/2 signaling pathway in ischemia-reperfusion injury. Front. Physiol. 10, 1038 (2019)","journal-title":"Front. Physiol."},{"issue":"8","key":"10197_CR113","doi-asserted-by":"publisher","first-page":"E643","DOI":"10.1152\/ajpendo.00445.2015","volume":"310","author":"K Ozaki","year":"2016","unstructured":"Ozaki, K., Awazu, M., Tamiya, M., Iwasaki, Y., Harada, A., Kugisaki, S., et al.: Targeting the ERK signaling pathway as a potential treatment for insulin resistance and type 2 diabetes. American Journal of Physiology-Endocrinology and Metabolism 310(8), E643\u2013E51 (2016)","journal-title":"American Journal of Physiology-Endocrinology and Metabolism"},{"issue":"5","key":"10197_CR114","doi-asserted-by":"publisher","first-page":"E625","DOI":"10.1152\/ajpendo.00480.2019","volume":"318","author":"L Zhang","year":"2020","unstructured":"Zhang, L., Chen, Z., Wang, Y., Tweardy, D.J., Mitch, W.E.: Stat3 activation induces insulin resistance via a muscle-specific E3 ubiquitin ligase Fbxo40. Am. J. Physiology-Endocrinology Metabolism. 318(5), E625\u2013E35 (2020)","journal-title":"Am. J. Physiology-Endocrinology Metabolism"},{"key":"10197_CR115","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.01035","volume":"11","author":"A Gabryelska","year":"2020","unstructured":"Gabryelska, A., Karuga, F.F., Szmyd, B., Bia\u0142asiewicz, P.: HIF-1\u03b1 as a mediator of insulin resistance, T2DM, and its complications: Potential links with obstructive sleep apnea. Front. Physiol. 11, 1035 (2020)","journal-title":"Front. Physiol."},{"issue":"4","key":"10197_CR116","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0093856","volume":"9","author":"Y Kihira","year":"2014","unstructured":"Kihira, Y., Miyake, M., Hirata, M., Hoshina, Y., Kato, K., Shirakawa, H., et al.: Deletion of hypoxia-inducible factor-1\u03b1 in adipocytes enhances glucagon-like peptide-1 secretion and reduces adipose tissue inflammation. PLoS One 9(4), e93856 (2014)","journal-title":"PLoS One"},{"issue":"13","key":"10197_CR117","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20133328","volume":"20","author":"N Kelley","year":"2019","unstructured":"Kelley, N., Jeltema, D., Duan, Y., He, Y.: The NLRP3 inflammasome: An overview of mechanisms of activation And regulation. Int. J. Mol. Sci. 20(13), 3328 (2019)","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10197_CR118","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23061447","volume":"23","author":"W Yu","year":"2018","unstructured":"Yu, W., Tao, M., Zhao, Y., Hu, X., Wang, M.: 4\u2032-Methoxyresveratrol alleviated AGE-induced inflammation via RAGE-mediated NF-\u03baB and NLRP3 inflammasome pathway. Molecules 23(6), 1447 (2018)","journal-title":"Molecules"},{"issue":"1","key":"10197_CR119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1478-811X-7-12","volume":"7","author":"A Riehl","year":"2009","unstructured":"Riehl, A., N\u00e9meth, J., Angel, P., Hess, J.: The receptor RAGE: Bridging inflammation and cancer. Cell Communication and Signaling 7(1), 1\u20137 (2009)","journal-title":"Cell Communication and Signaling"},{"issue":"1","key":"10197_CR120","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1189\/jlb.1012519","volume":"94","author":"K Kierdorf","year":"2013","unstructured":"Kierdorf, K., Fritz, G.: RAGE regulation and signaling in inflammation and beyond. J. Leukoc. Biol. 94(1), 55\u201368 (2013)","journal-title":"J. Leukoc. Biol."},{"issue":"1","key":"10197_CR121","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-26482-6","volume":"8","author":"DC Pinto-Junior","year":"2018","unstructured":"Pinto-Junior, D.C., Silva, K.S., Michalani, M.L., Yonamine, C.Y., Esteves, J.V., Fabre, N.T., et al.: Advanced glycation end products-induced insulin resistance involves repression of skeletal muscle GLUT4 expression. Sci. Rep. 8(1), 8109 (2018)","journal-title":"Sci. Rep."},{"issue":"1\u20132","key":"10197_CR122","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.mce.2013.01.019","volume":"370","author":"DT Furuya","year":"2013","unstructured":"Furuya, D.T., Neri, E.A., Poletto, A.C., Anh\u00ea, G., Freitas, H., Campello, R.S., et al.: Identification of nuclear factor-\u03baB sites in the Slc2a4 gene promoter. Mol. Cell. Endocrinol. 370(1\u20132), 87\u201395 (2013)","journal-title":"Mol. Cell. Endocrinol."},{"issue":"16","key":"10197_CR123","doi-asserted-by":"publisher","first-page":"8590","DOI":"10.3390\/ijms22168590","volume":"22","author":"M Khalid","year":"2021","unstructured":"Khalid, M., Alkaabi, J., Khan, M.A., Adem, A.: Insulin signal transduction perturbations in insulin resistance. Int. J. Mol. Sci. 22(16), 8590 (2021)","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10197_CR124","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3390\/biom5010194","volume":"5","author":"K Nowotny","year":"2015","unstructured":"Nowotny, K., Jung, T., H\u00f6hn, A., Weber, D., Grune, T.: Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules. 5(1), 194\u2013222 (2015)","journal-title":"Biomolecules"},{"issue":"5","key":"10197_CR125","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ceca.2014.08.006","volume":"56","author":"A Guerrero-Hern\u00e1ndez","year":"2014","unstructured":"Guerrero-Hern\u00e1ndez, A., Leon-Aparicio, D., Chavez-Reyes, J., Olivares-Reyes, J.A., DeJesus, S.: Endoplasmic reticulum stress in insulin resistance and diabetes. Cell. Calcium. 56(5), 311\u2013322 (2014)","journal-title":"Cell. Calcium"},{"issue":"5","key":"10197_CR126","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.bj.2017.06.007","volume":"40","author":"S Hurrle","year":"2017","unstructured":"Hurrle, S., Hsu, W.H.: The etiology of oxidative stress in insulin resistance. Biomedical Journal 40(5), 257\u2013262 (2017)","journal-title":"Biomedical Journal"},{"issue":"1","key":"10197_CR127","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cellsig.2008.10.004","volume":"21","author":"JH Lim","year":"2009","unstructured":"Lim, J.H., Lee, H.J., Jung, M.H., Song, J.: Coupling mitochondrial dysfunction to Endoplasmic reticulum stress response: A molecular mechanism leading to hepatic insulin resistance. Cell. Signal. 21(1), 169\u2013177 (2009)","journal-title":"Cell. Signal."},{"key":"10197_CR128","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1007\/s00125-012-2644-8","volume":"55","author":"K Copps","year":"2012","unstructured":"Copps, K., White, M.: Regulation of insulin sensitivity by serine\/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2. Diabetologia. 55, 2565\u20132582 (2012)","journal-title":"Diabetologia"},{"issue":"5\u20136","key":"10197_CR129","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.vph.2012.05.005","volume":"57","author":"A Ceriello","year":"2012","unstructured":"Ceriello, A.: The emerging challenge in diabetes: The metabolic memory. Vascular Pharmacology 57(5\u20136), 133\u2013138 (2012)","journal-title":"Vascular Pharmacology"},{"issue":"1","key":"10197_CR130","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-015-0176-5","volume":"14","author":"S Yamagishi","year":"2015","unstructured":"Yamagishi, S., Fukami, K., Matsui, T.: Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications. Cardiovasc. Diabetol. 14(1), 1\u201312 (2015)","journal-title":"Cardiovasc. Diabetol."},{"key":"10197_CR131","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s11427-014-4710-6","volume":"57","author":"E Zhang","year":"2014","unstructured":"Zhang, E., Wu, Y.: Metabolic memory: Mechanisms and implications for diabetic vasculopathies. Sci. China Life Sci. 57, 845\u2013851 (2014)","journal-title":"Sci. China Life Sci."},{"key":"10197_CR132","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/6989453","author":"K Papatheodorou","year":"2016","unstructured":"Papatheodorou, K., Papanas, N., Banach, M., Papazoglou, D., Edmonds, M.: Complications of Diabetes 2016. Journal of Diabetes Research (2016). https:\/\/doi.org\/10.1155\/2016\/6989453","journal-title":"Journal of Diabetes Research"},{"issue":"1","key":"10197_CR133","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.tem.2013.08.002","volume":"25","author":"MB Manigrasso","year":"2014","unstructured":"Manigrasso, M.B., Juranek, J., Ramasamy, R., Schmidt, A.M.: Unlocking the biology of RAGE in diabetic microvascular complications. Trends Endocrinol. Metabolism. 25(1), 15\u201322 (2014)","journal-title":"Trends Endocrinol. Metabolism"},{"issue":"9","key":"10197_CR134","first-page":"1615","volume":"13","author":"C Tobon-Velasco","year":"2014","unstructured":"Tobon-Velasco, C., Cuevas, J., Torres-Ramos, E.A.: Receptor for ages (RAGE) as mediator of NF-kB pathway activation in neuroinflammation and oxidative stress. CNS & neurological Disorders-Drug targets (Formerly current drug targets-CNS. Neurol. Disorders). 13(9), 1615\u20131626 (2014)","journal-title":"Neurol. Disorders)"},{"issue":"14","key":"10197_CR135","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.2174\/13816128113199990475","volume":"20","author":"K Fukami","year":"2014","unstructured":"Fukami, K., Yamagishi, S., Okuda, S.: Role of AGEs-RAGE system in cardiovascular disease. Current Pharmaceutical Design 20(14), 2395\u20132402 (2014)","journal-title":"Current Pharmaceutical Design"},{"issue":"11","key":"10197_CR136","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1093\/nutrit\/nuv030","volume":"73","author":"NJ Kellow","year":"2015","unstructured":"Kellow, N.J., Coughlan, M.T.: Effect of diet-derived advanced glycation end products on inflammation. Nutr. Rev. 73(11), 737\u2013759 (2015)","journal-title":"Nutr. Rev."},{"issue":"5","key":"10197_CR137","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1161\/CIRCRESAHA.109.212217","volume":"106","author":"SF Yan","year":"2010","unstructured":"Yan, S.F., Ramasamy, R., Schmidt, A.M.: The RAGE axis: A fundamental mechanism signaling danger to the vulnerable vasculature. Circul. Res. 106(5), 842\u2013853 (2010)","journal-title":"Circul. Res."},{"issue":"2","key":"10197_CR138","doi-asserted-by":"publisher","DOI":"10.3390\/jcm6020022","volume":"6","author":"K Cervantes Gracia","year":"2017","unstructured":"Cervantes Gracia, K., Llanas-Cornejo, D., Husi, H.: CVD and oxidative stress. Journal of Clinical Medicine 6(2), 22 (2017)","journal-title":"Journal of Clinical Medicine"},{"key":"10197_CR139","doi-asserted-by":"crossref","unstructured":"Kay, A.M., Simpson, C.L., Stewart, J.A.: The role of AGE\/RAGE signaling in diabetes-mediated vascular calcification. Journal of diabetes research. ;2016. (2016)","DOI":"10.1155\/2016\/6809703"},{"issue":"1","key":"10197_CR140","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000369126","volume":"130","author":"F Li","year":"2015","unstructured":"Li, F., Zhao, Z., Cai, Z., Dong, N., Liu, Y.: Oxidized low-density lipoprotein promotes osteoblastic differentiation of valvular interstitial cells through RAGE\/MAPK. Cardiology. 130(1), 55\u201361 (2015)","journal-title":"Cardiology"},{"issue":"2","key":"10197_CR141","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1093\/cvr\/cvp036","volume":"82","author":"L Sun","year":"2009","unstructured":"Sun, L., Ishida, T., Yasuda, T., Kojima, Y., Honjo, T., Yamamoto, Y., et al.: RAGE mediates oxidized LDL-induced pro-inflammatory effects and atherosclerosis in non-diabetic LDL receptor-deficient mice. Cardiovascular. Res. 82(2), 371\u2013381 (2009)","journal-title":"Cardiovascular. Res."},{"issue":"5","key":"10197_CR142","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1089\/rej.2017.2025","volume":"21","author":"S Yamagishi","year":"2018","unstructured":"Yamagishi, S., Matsui, T.: Role of ligands of receptor for advanced glycation end products (RAGE) in peripheral artery disease. Rejuven. Res. 21(5), 456\u2013463 (2018)","journal-title":"Rejuven. Res."},{"key":"10197_CR143","doi-asserted-by":"publisher","first-page":"486","DOI":"10.2741\/3700","volume":"16","author":"SPS-JY Hyun","year":"2011","unstructured":"Hyun, S.P.S.-J.Y., Shim, J.: RAGE and cardiovascular disease. Front. Biosci. 16, 486\u2013497 (2011)","journal-title":"Front. Biosci."},{"key":"10197_CR144","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ejphar.2018.06.001","volume":"833","author":"D Sanajou","year":"2018","unstructured":"Sanajou, D., Ghorbani Haghjo, A., Argani, H., Aslani, S.: AGE-RAGE axis Blockade in diabetic nephropathy: Current status and future directions. Eur. J. Pharmacol. 833, 158\u2013164 (2018)","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10197_CR145","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.amjhyper.2006.08.009","volume":"20","author":"M McNulty","year":"2007","unstructured":"McNulty, M., Mahmud, A., Feely, J.: Advanced glycation End-Products and arterial stiffness in hypertension. American Journal of Hypertension 20(3), 242\u2013247 (2007)","journal-title":"American Journal of Hypertension"},{"issue":"1","key":"10197_CR146","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ijcard.2007.10.047","volume":"132","author":"KM Choi","year":"2009","unstructured":"Choi, K.M., Yoo, H.J., Kim, H.Y., Lee, K.W., Seo, J.A., Kim, S.G., et al.: Association between endogenous secretory RAGE, inflammatory markers and arterial stiffness. Int. J. Cardiol. 132(1), 96\u2013101 (2009)","journal-title":"Int. J. Cardiol."},{"issue":"3","key":"10197_CR147","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s00223-015-9985-5","volume":"97","author":"M Saito","year":"2015","unstructured":"Saito, M., Marumo, K.: Effects of collagen crosslinking on bone material properties in health and disease. Calcif. Tissue Int. 97(3), 242\u2013261 (2015)","journal-title":"Calcif. Tissue Int."},{"issue":"1\u20133","key":"10197_CR148","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1159\/000485146","volume":"45","author":"M London Gerard","year":"2018","unstructured":"London Gerard, M.: Arterial stiffness in chronic kidney disease and End-Stage renal disease. Blood Purif. 45(1\u20133), 154\u2013158 (2018)","journal-title":"Blood Purif."},{"issue":"1","key":"10197_CR149","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-015-0176-5","volume":"14","author":"S Yamagishi","year":"2015","unstructured":"Yamagishi, S., Fukami, K., Matsui, T.: Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications. Cardiovasc. Diabetol. 14(1), 2 (2015)","journal-title":"Cardiovasc. Diabetol."},{"issue":"7","key":"10197_CR150","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.3390\/ijms23073439","volume":"23","author":"M Steenbeke","year":"2022","unstructured":"Steenbeke, M., Speeckaert, R., Desmedt, S., Glorieux, G., Delanghe, J.R., Speeckaert, M.M.: The role of advanced glycation end products and its soluble receptor in kidney diseases. Int. J. Mol. Sci. 23(7), 3439 (2022)","journal-title":"Int. J. Mol. Sci."},{"key":"10197_CR151","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00798","author":"SV Suryavanshi","year":"2017","unstructured":"Suryavanshi, S.V., Kulkarni, Y.A.: NF-\u03ba\u03b2: A potential target in the management of vascular complications of diabetes. Front. Pharmacol (2017). https:\/\/doi.org\/10.3389\/fphar.2017.00798","journal-title":"Front. Pharmacol"},{"key":"10197_CR152","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2020.101799","volume":"37","author":"Q Kang","year":"2020","unstructured":"Kang, Q., Yang, C.: Oxidative stress and diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications. Redox Biology 37, 101799 (2020)","journal-title":"Redox Biology"},{"key":"10197_CR153","doi-asserted-by":"publisher","first-page":"3164734","DOI":"10.1155\/2016\/3164734","volume":"2016","author":"M Nita","year":"2016","unstructured":"Nita, M., Grzybowski, A.: The role of the reactive oxygen species and oxidative stress in the pathomechanism of the Age-Related ocular diseases and other pathologies of the anterior and posterior eye segments in adults. Oxidative Med. Cell. Longev. 2016, 3164734 (2016)","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10197_CR154","doi-asserted-by":"publisher","first-page":"6989453","DOI":"10.1155\/2016\/6989453","volume":"2016","author":"K Papatheodorou","year":"2016","unstructured":"Papatheodorou, K., Papanas, N., Banach, M., Papazoglou, D., Edmonds, M.: Complications of diabetes 2016. J. Diabetes Res. 2016, 6989453 (2016)","journal-title":"J. Diabetes Res."},{"issue":"1","key":"10197_CR155","doi-asserted-by":"publisher","DOI":"10.1038\/srep17637","volume":"5","author":"DV Ilatovskaya","year":"2015","unstructured":"Ilatovskaya, D.V., Levchenko, V., Lowing, A., Shuyskiy, L.S., Palygin, O., Staruschenko, A.: Podocyte injury in diabetic nephropathy: Implications of angiotensin II \u2013 dependent activation of TRPC channels. Sci. Rep. 5(1), 17637 (2015)","journal-title":"Sci. Rep."},{"issue":"1","key":"10197_CR156","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/j.1749-6632.2011.06320.x","volume":"1243","author":"R Ramasamy","year":"2011","unstructured":"Ramasamy, R., Yan, S.F., Schmidt, A.M.: Receptor for AGE (RAGE): Signaling mechanisms in the pathogenesis of diabetes and its complications. Ann. N. Y. Acad. Sci. 1243(1), 88\u2013102 (2011)","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10197_CR157","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.mce.2017.05.004","volume":"470","author":"X An","year":"2018","unstructured":"An, X., Zhang, L., Yao, Q., Li, L., Wang, B., Zhang, J., et al.: The receptor for advanced glycation endproducts mediates podocyte heparanase expression through NF-\u03baB signaling pathway. Mol. Cell. Endocrinol. 470, 14\u201325 (2018)","journal-title":"Mol. Cell. Endocrinol."},{"key":"10197_CR158","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.neulet.2016.04.046","volume":"625","author":"R Al-Haddad","year":"2016","unstructured":"Al-Haddad, R., Karnib, N., Assaad, R.A., Bilen, Y., Emmanuel, N., Ghanem, A., et al.: Epigenetic changes in diabetes. Neurosci. Lett. 625, 64\u201369 (2016)","journal-title":"Neurosci. Lett."},{"issue":"12","key":"10197_CR159","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrendo.2010.188","volume":"6","author":"L Pirola","year":"2010","unstructured":"Pirola, L., Balcerczyk, A., Okabe, J., El-Osta, A.: Epigenetic phenomena linked to diabetic complications. Nature Reviews Endocrinology 6(12), 665\u2013675 (2010)","journal-title":"Nature Reviews Endocrinology"},{"issue":"3","key":"10197_CR160","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00125-014-3462-y","volume":"58","author":"MA Reddy","year":"2015","unstructured":"Reddy, M.A., Zhang, E., Natarajan, R.: Epigenetic mechanisms in diabetic complications and metabolic memory. Diabetologia 58(3), 443\u2013455 (2015)","journal-title":"Diabetologia"},{"issue":"11","key":"10197_CR161","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.2174\/1389450116666150722141418","volume":"17","author":"C Sourris","year":"2016","unstructured":"Sourris, C., Yao, K., Jerums, H., E Cooper, G., I Ekinci, M., Coughlan, E.T.: Can targeting the incretin pathway dampen RAGE-mediated events in diabetic nephropathy? Curr. Drug Targets. 17(11), 1252\u20131264 (2016)","journal-title":"Curr. Drug Targets"},{"issue":"7","key":"10197_CR162","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11072085","volume":"11","author":"W Fr\u0105k","year":"2023","unstructured":"Fr\u0105k, W., Hajdys, J., Radzioch, E., Szlagor, M., M\u0142ynarska, E., Rysz, J., et al.: Cardiovascular diseases: Therapeutic potential of SGLT-2 inhibitors. Biomedicines 11(7), 2085 (2023)","journal-title":"Biomedicines"},{"issue":"6","key":"10197_CR163","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1210\/clinem\/dgab078","volume":"106","author":"KM Love","year":"2021","unstructured":"Love, K.M., Liu, Z.: DPP4 activity, hyperinsulinemia, and atherosclerosis. The Journal of Clinical Endocrinology & Metabolism 106(6), 1553\u20131565 (2021)","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"issue":"18","key":"10197_CR164","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184357","volume":"20","author":"Y-Y Chen","year":"2019","unstructured":"Chen, Y.-Y., Wu, T.-T., Ho, C.-Y., Yeh, T.-C., Sun, G.-C., Kung, Y.-H., et al.: Dapagliflozin prevents NOX- and SGLT2-Dependent oxidative stress in lens cells exposed to Fructose-Induced diabetes mellitus. Int. J. Mol. Sci. 20(18), 4357 (2019)","journal-title":"Int. J. Mol. Sci."},{"key":"10197_CR165","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.biopha.2018.03.176","volume":"103","author":"AF Abdel-Wahab","year":"2018","unstructured":"Abdel-Wahab, A.F., Bamagous, G.A., Al-Harizy, R.M., ElSawy, N.A., Shahzad, N., Ibrahim, I.A., et al.: Renal protective effect of SGLT2 inhibitor Dapagliflozin alone and in combination with Irbesartan in a rat model of diabetic nephropathy. Biomedicine & Pharmacotherapy 103, 59\u201366 (2018)","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"11","key":"10197_CR166","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112394","volume":"9","author":"M Oelze","year":"2014","unstructured":"Oelze, M., Kr\u00f6ller-Sch\u00f6n, S., Welschof, P., Jansen, T., Hausding, M., Mikhed, Y., et al.: The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PloS One 9(11), e112394 (2014)","journal-title":"PloS One"},{"issue":"1","key":"10197_CR167","doi-asserted-by":"publisher","first-page":"593","DOI":"10.18632\/aging.102643","volume":"12","author":"MK Sarker","year":"2020","unstructured":"Sarker, M.K., Lee, J.H., Lee, D.H., Chun, K.H., Jun, H.S.: Attenuation of diabetic kidney injury in DPP4-deficient rats; role of GLP-1 on the suppression of AGE formation by inducing glyoxalase 1. Aging (Albany NY) 12(1), 593\u2013610 (2020)","journal-title":"Aging (Albany NY)"},{"key":"10197_CR168","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-015-0176-5","volume":"14","author":"S Yamagishi","year":"2015","unstructured":"Yamagishi, S., Fukami, K., Matsui, T.: Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications. Cardiovasc. Diabetol. 14, 1\u201312 (2015)","journal-title":"Cardiovasc. Diabetol."},{"issue":"4\u20135","key":"10197_CR169","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.clinbiochem.2012.11.023","volume":"46","author":"N Tahara","year":"2013","unstructured":"Tahara, N., Yamagishi, S., Takeuchi, M., Tahara, A., Kaifu, K., Ueda, S., et al.: Serum levels of advanced glycation end products (AGEs) are independently correlated with Circulating levels of dipeptidyl peptidase-4 (DPP-4) in humans. Clin. Biochem. 46(4\u20135), 300\u2013303 (2013)","journal-title":"Clin. Biochem."},{"key":"10197_CR170","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2840-12-125","volume":"12","author":"Y Ishibashi","year":"2013","unstructured":"Ishibashi, Y., Matsui, T., Maeda, S., Higashimoto, Y., Yamagishi, S.: Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate\/insulin-like growth factor II receptor. Cardiovasc. Diabetol. 12, 1\u20139 (2013)","journal-title":"Cardiovasc. Diabetol."},{"issue":"10","key":"10197_CR171","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1055\/s-0034-1371892","volume":"46","author":"S Nakashima","year":"2014","unstructured":"Nakashima, S., Matsui, T., Takeuchi, M., Yamagishi, S.I.: Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end Products-Receptor axis. Horm. Metab. Res. 46(10), 717\u2013721 (2014)","journal-title":"Horm. Metab. Res."},{"issue":"1","key":"10197_CR172","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-97361-w","volume":"11","author":"C-P Lin","year":"2021","unstructured":"Lin, C.-P., Huang, P.-H., Chen, C.-Y., Wu, M.-Y., Chen, J.-S., Chen, J.-W., et al.: Sitagliptin attenuates arterial calcification by downregulating oxidative stress-induced receptor for advanced glycation end products in LDLR knockout mice. Sci. Rep. 11(1), 17851 (2021)","journal-title":"Sci. Rep."},{"key":"10197_CR173","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00202","volume":"10","author":"W Ding","year":"2019","unstructured":"Ding, W., Wang, J.: Exenatide protects against cardiac dysfunction by attenuating oxidative stress in the diabetic mouse heart. Front. Endocrinol. 10, 445348 (2019)","journal-title":"Front. Endocrinol."},{"issue":"4","key":"10197_CR174","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.3892\/etm.2014.1873","volume":"8","author":"B Yi","year":"2014","unstructured":"Yi, B., Hu, X., Wen, Z., Zhang, T., Cai, Y.: Exendin-4, a glucagon\u2013like peptide\u20131 receptor agonist, inhibits hyperglycemia\u2013induced apoptosis in myocytes by suppressing receptor for advanced glycation end products expression. Exp. Ther. Med. 8(4), 1185\u20131190 (2014)","journal-title":"Exp. Ther. Med."},{"key":"10197_CR175","doi-asserted-by":"publisher","first-page":"108667","DOI":"10.1016\/j.biopha.2019.108667","volume":"113","author":"S Tang","year":"2019","unstructured":"Tang, S., Tang, H., Su, H., Wang, Y., Zhou, Q., Zhang, Q., et al.: Glucagon-like peptide-1 attenuates endothelial barrier injury in diabetes via cAMP\/PKA mediated down-regulation of MLC phosphorylation. Biomed. Pharmacother. 113, 108667 (2019)","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10197_CR176","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.kint.2023.09.029","volume":"105","author":"KC Sourris","year":"2024","unstructured":"Sourris, K.C., Ding, Y., Maxwell, S.S., Al-sharea, A., Kantharidis, P., Mohan, M., et al.: Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products\u2013induced inflammation. Kidney Int 105(1), 132\u2013149 (2024)","journal-title":"Kidney Int"},{"key":"10197_CR177","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1007\/s00125-010-1837-2","volume":"53","author":"KC Sourris","year":"2010","unstructured":"Sourris, K.C., Morley, A.L., Koitka, A., Samuel, P., Coughlan, M.T., Penfold, S.A., et al.: Receptor for ages (RAGE) Blockade May exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor. Diabetologia. 53, 2442\u20132451 (2010)","journal-title":"Diabetologia"},{"issue":"3","key":"10197_CR178","doi-asserted-by":"publisher","first-page":"F763","DOI":"10.1152\/ajprenal.00591.2009","volume":"298","author":"AL Tan","year":"2010","unstructured":"Tan, A.L., Sourris, K.C., Harcourt, B.E., Thallas-Bonke, V., Penfold, S., Andrikopoulos, S., et al.: Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy. American Journal of Physiology-Renal Physiology 298(3), F763\u2013F70 (2010)","journal-title":"American Journal of Physiology-Renal Physiology"},{"key":"10197_CR179","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.peptides.2017.08.003","volume":"100","author":"B Pang","year":"2018","unstructured":"Pang, B., Zhou, H., Kuang, H.: The potential benefits of glucagon-like peptide-1 receptor agonists for diabetic retinopathy. Peptides. 100, 123\u2013126 (2018)","journal-title":"Peptides"},{"issue":"13","key":"10197_CR180","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23137142","volume":"23","author":"Y-Y Chen","year":"2022","unstructured":"Chen, Y.-Y., Wu, T.-T., Ho, C.-Y., Yeh, T.-C., Sun, G.-C., Tseng, C.-J., et al.: Blocking of SGLT2 to eliminate NADPH-Induced oxidative stress in lenses of animals with Fructose-Induced diabetes mellitus. Int. J. Mol. Sci. 23(13), 7142 (2022)","journal-title":"Int. J. Mol. Sci."},{"key":"10197_CR181","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.122005","volume":"330","author":"Y-Y Chen","year":"2023","unstructured":"Chen, Y.-Y., Chen, C.-K., Wu, T.-T., Ho, C.-Y., Yeh, T.-C., Sun, G.-C., et al.: Attenuation of epithelial-mesenchymal transition via SGLT2 Inhibition and diabetic cataract suppression by Dapagliflozin nanoparticles treatment. Life Sci 330, 122005 (2023)","journal-title":"Life Sci"},{"issue":"2","key":"10197_CR182","doi-asserted-by":"publisher","first-page":"H246","DOI":"10.1152\/ajpheart.00438.2021","volume":"322","author":"S Wang","year":"2022","unstructured":"Wang, S., Jiao, F., Border, J.J., Fang, X., Crumpler, R.F., Liu, Y., et al.: Luseogliflozin, a sodium-glucose cotransporter-2 inhibitor, reverses cerebrovascular dysfunction and cognitive impairments in 18-mo-old diabetic animals. Am. J. Physiol. Heart Circ. Physiol. 322(2), H246\u2013H59 (2022)","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"11","key":"10197_CR183","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.5551\/jat.52100","volume":"27","author":"A Rahadian","year":"2020","unstructured":"Rahadian, A., Fukuda, D., Salim, H.M., Yagi, S., Kusunose, K., Yamada, H., et al.: Canagliflozin prevents diabetes-induced vascular dysfunction in ApoE-deficient mice. Journal of Atherosclerosis and Thrombosis 27(11), 1141\u20131151 (2020)","journal-title":"Journal of Atherosclerosis and Thrombosis"},{"key":"10197_CR184","doi-asserted-by":"crossref","unstructured":"Liu, Z., Chen, J., Sun, L., Li, J., Sun, H.: Empagliflozin Alleviates Diabetic Renal Tubular Lipid Accumulation and NLRP3 Inflammasome Activation Through AGEs-RAGE Pathway. (2021)","DOI":"10.21203\/rs.3.rs-870754\/v1"},{"issue":"4","key":"10197_CR185","first-page":"384","volume":"22","author":"Z Ashrafi Jigheh","year":"2019","unstructured":"Ashrafi Jigheh, Z., Ghorbani Haghjo, A., Argani, H., Roshangar, L., Rashtchizadeh, N., Sanajou, D., et al.: Empagliflozin alleviates renal inflammation and oxidative stress in streptozotocin-induced diabetic rats partly by repressing HMGB1-TLR4 receptor axis. Iran. J. Basic. Med. Sci. 22(4), 384\u2013390 (2019)","journal-title":"Iran. J. Basic. Med. Sci."},{"issue":"4","key":"10197_CR186","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/ddr.21779","volume":"82","author":"R Kumar","year":"2021","unstructured":"Kumar, R., Bhargava, P., Suchal, K., Bhatia, J., Arya, D.S.: Targeting AGE-RAGE signaling pathway by saxagliptin prevents myocardial injury in isoproterenol challenged diabetic rats. Drug Dev. Res. 82(4), 589\u2013597 (2021)","journal-title":"Drug Dev. Res."},{"issue":"1","key":"10197_CR187","doi-asserted-by":"publisher","first-page":"525","DOI":"10.18632\/aging.202162","volume":"13","author":"H Zhang","year":"2020","unstructured":"Zhang, H., Chu, Y., Zheng, H., Wang, J., Song, B., Sun, Y.: Liraglutide improved the cognitive function of diabetic mice via the receptor of advanced glycation end products down-regulation. Aging (Albany NY) 13(1), 525\u2013536 (2020)","journal-title":"Aging (Albany NY)"},{"key":"10197_CR188","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.peptides.2018.11.008","volume":"112","author":"B Di","year":"2019","unstructured":"Di, B., Li, H.-W., Li, W., Hua, B.: Liraglutide inhibited ages induced coronary smooth muscle cell phenotypic transition through inhibiting the NF-\u03baB signal pathway. Peptides. 112, 125\u2013132 (2019)","journal-title":"Peptides"}],"container-title":["Glycoconjugate Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10719-025-10197-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10719-025-10197-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10719-025-10197-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T18:16:37Z","timestamp":1764180997000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10719-025-10197-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":188,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10197"],"URL":"https:\/\/doi.org\/10.1007\/s10719-025-10197-8","relation":{},"ISSN":["0282-0080","1573-4986"],"issn-type":[{"type":"print","value":"0282-0080"},{"type":"electronic","value":"1573-4986"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"1 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}